Quick Answer
NORTHWEST BIOTHERAPEUTICS INC reported Operating Income Loss of -$66.51 million for the year ending 2024.
- NORTHWEST BIOTHERAPEUTICS INC showed a decrease of -19.8% in Operating Income Loss from 2023 to 2024.
- This data is from NORTHWEST BIOTHERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2010 to 2024 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2010 to 2024), NORTHWEST BIOTHERAPEUTICS INC's Operating Income Loss has declined by 333.2%.
- Historical annual values: Fiscal year 2024: -$66.51 million | Fiscal year 2023: -$55.51 million | Fiscal year 2022: -$67.18 million | Fiscal year 2021: -$52.70 million | Fiscal year 2020: -$86.61 million | Fiscal year 2019: -$27.98 million | Fiscal year 2018: -$41.48 million | Fiscal year 2017: -$54.68 million | Fiscal year 2016: -$79.27 million | Fiscal year 2015: -$126.28 million | Fiscal year 2014: -$101.14 million | Fiscal year 2013: -$55.47 million | Fiscal year 2012: -$43.83 million | Fiscal year 2011: -$26.79 million | Fiscal year 2010: -$15.35 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: